Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.80 |
| ▸ | MAPT | P10636 | 6/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.80 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.80 |
| ▸ | TSHR | P16473 | 5/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | THPO | P40225 | 3/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.80 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.80 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aranidipine SCHEMBL29661509 | 1.00 | CYP1A2 (0.80) | CYP1A2ADORA3CYP3A4CYP2C9CYP2C19 | |
| Aranidipine SCHEMBL49911 | 1.00 | CYP1A2 (0.80) | CYP1A2ADORA3CYP3A4CYP2C9CYP2C19 | |
| Aranidipine SCHEMBL27770888 | 0.99 | CYP1A2 (0.79) | CYP1A2ADORA3CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL28770057 | 0.91 | CACNA1B (0.70) | CYP1A2ADORA3CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5085498 | 0.90 | ADORA3 (0.86) | CYP1A2ADORA3CYP3A4CYP2C9CYP2C19 | |
| Nifedipine SCHEMBL3968 | 0.90 | ADORA3 (1.00) | CYP1A2ADORA3CYP3A4CYP2C9CYP2C19 | |
| Nifedipine SCHEMBL29349595 | 0.90 | ADORA3 (1.00) | CYP1A2ADORA3CYP3A4CYP2C9CYP2C19 | |
| Nifedipine SCHEMBL1172946 | 0.90 | ADORA3 (1.00) | CYP1A2ADORA3CYP3A4CYP2C9CYP2C19 | |
| Nifedipine SCHEMBL28674741 | 0.89 | ADORA3 (0.93) | CYP1A2ADORA3CYP3A4CYP2C9CYP2C19 | |
| Nifedipine SCHEMBL8851402 | 0.89 | ADORA3 (0.97) | CYP1A2ADORA3CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5003 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-13 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-22 | — | — | US | claimed |
| EP-4529461-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | Idorsia Pharmaceuticals Ltd (CH) | 2025-04-02 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. | 2024-09-12 | — | — | US | claimed |
| WO-2024150130-A2 | NECROSIS INHIBITOR | LINKGEVITY LIMITED (GB) | 2024-07-18 | — | — | WO | claimed |
| WO-2002060461-A1 | BLOOD BRAIN BARRIER MODULATION USING STRESSED AUTOLOGOUS BLOOD CELLS | VASOGEN IRELAND LIMITED (IE) | 2002-08-08 | — | — | WO | claimed |
| WO-2002043806-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC (US) | 2002-06-06 | — | — | WO | claimed |
| US-20020061835-A1 | Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream | RHEOLOGICS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | SCHUH JOSEPH R (US) | 2002-04-11 | — | — | US | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002009761-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |
| CN-1315945-A | Nitrate salts of antihypertensive drugs | NICOX SA (FR) | 2001-10-03 | — | — | CN | claimed |
| EP-1087953-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 2001-04-04 | — | — | EP | claimed |
| WO-1999067231-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 1999-12-29 | — | — | WO | claimed |